Published in Ann Intern Med on May 15, 1993
Oxidative stress in prostate cancer. Cancer Lett (2009) 2.28
Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer (2009) 1.74
Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health (2009) 1.74
Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer (2000) 1.73
Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc (1999) 1.67
Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer (1999) 1.31
Metastasis of genitourinary tumors to the head and neck region. Eur Arch Otorhinolaryngol (2009) 1.27
Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem (2008) 1.17
Attitudes of African Americans regarding screening for prostate cancer. J Natl Med Assoc (1996) 1.16
Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer (1998) 1.16
microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer (2013) 1.14
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate (2008) 1.11
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer (2008) 1.05
Common 8q24 sequence variations are associated with Asian Indian advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.03
Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br J Cancer (1999) 1.02
Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med (2000) 1.02
Genetical toxicogenomics in Drosophila identifies master-modulatory loci that are regulated by developmental exposure to lead. Neurotoxicology (2009) 1.01
Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese. PLoS One (2012) 0.96
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Cancer, physical activity, and exercise. Compr Physiol (2012) 0.94
Diet, vegetarian food and prostate carcinoma among men in Taiwan. Br J Cancer (2005) 0.92
Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract (2002) 0.92
Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol (2011) 0.90
Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer (2015) 0.90
CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer (2003) 0.89
Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer. Cancer Control (2009) 0.89
The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int (2015) 0.88
Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. Br J Gen Pract (2011) 0.85
A comparative study of recombinant and native frutalin binding to human prostate tissues. BMC Biotechnol (2009) 0.84
Susceptibility of XPD and hOGG1 genetic variants to prostate cancer. Biomed Rep (2013) 0.82
The association of XRCC3 Thr241Met genetic variant with risk of prostate cancer: a meta-analysis. Afr Health Sci (2015) 0.81
Antibiotic and anti-inflammatory use and the risk of prostate cancer. BMC Res Notes (2009) 0.81
Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res (2014) 0.81
Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer. Oncol Lett (2012) 0.81
Sex specific retinoic acid signaling is required for the initiation of urogenital sinus bud development. Dev Biol (2014) 0.80
Prostate cancer survival in Trinidad: Is PSA a prognostic factor? Can Urol Assoc J (2011) 0.80
Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget (2016) 0.80
The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc (2000) 0.79
Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow. J Cell Biochem (2016) 0.79
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian J Clin Biochem (2006) 0.78
DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis. Neoplasia (2016) 0.77
XPC intron11 C/A polymorphism as a risk factor for prostate cancer. Environ Health Prev Med (2016) 0.77
Strategies for prostate cancer prevention: Review of the literature. Indian J Urol (2008) 0.77
Beyond the limits of oxygen: effects of hypoxia in a hormone-independent prostate cancer cell line. ISRN Oncol (2013) 0.76
Molecular genetics of prostate cancer: clinical applications. J Natl Med Assoc (1998) 0.75
Comparison of 4-hydroxynonenal-induced p53-mediated apoptosis in prostate cancer cells LNCaP and DU145. Contemp Oncol (Pozn) (2014) 0.75
The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. PeerJ (2016) 0.75
Minimally invasive prostate cancer detection test using FISH probes. Res Rep Urol (2016) 0.75
Incidence of prostate and urological cancers in England by ethnic group, 2001-2007: a descriptive study. BMC Cancer (2015) 0.75
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol (1994) 1.56
Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol (1997) 0.83
Is dietary fat a risk factor for prostate cancer? J Natl Cancer Inst (1993) 0.80
Epidemiology of prostate cancer: molecular and environmental clues. Urology (1996) 0.79
The Hospice Supportive Care Program: a new "transitionless" model of palliative care for patients with incurable prostate cancer. J Natl Cancer Inst (1996) 0.79
A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology (1997) 0.76
Research and the staff nurse. J Nurs Staff Dev (1988) 0.75
Discharge planning--a quality assurance approach. Nurs Manage (1988) 0.75
A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate. Am J Clin Oncol (1996) 0.75